Kangh's IPO on Shenzhen Stock Exchange

According to VCBeat, on June 17, 2020, Chengdu Kanghua Biological Products Co., Ltd. ("Kangh", stock code:300841) started trading on the Shenzhen ChiNext Market, at a public offering price of RMB 70.37 per share, raising RMB 1.06 billion. Its initial listing shares account for 25% of total outstanding shares. The company's initial price-to-earning ratio (PE) stands at 22.99.

Minsheng Securities acted as the lead underwriter and sponsor for the IPO.

After the opening, the IPO of Kangh quickly hit the limit of 44% increment. The opening price was 84.44 yuan per share, and the price earlier in today was 101.33 yuan per share, with the market value of 6.08 billion yuan. The funds raised from this listing will be mainly used for the construction of the vaccine production base and R&D center in Wenjiang.

Founded in 2004, Kangh is one of the 13 enterprises with full vaccine production capacity in Chengdu Economic and Technological Development Zone, covering an area of 30000 square meters. Kangh is principally involved in the research and development, manufacturing and sales of vaccine products for prevention. The company's main products are Rabies Vaccine (human diploid cell) for Human Use, Freeze-dried and Group ACYW135 Meningococcal Polysaccharide Vaccine. The company distributes its products in the domestic market and to overseas markets.

Kangh is equipped with the world-class biotechnology experimental center, SPF experimental animal center, high-tech GMP production workshop for bacterial and viral vaccines. 

From 2017 to 2018, Kangh obtained three investments from Yingke PE. 

In the next three years, regarding research and development as the core, and production and quality of products as the foundation, Kangh will strive to become "the leading company of Rabies Vaccine (human diploid cell)" and a top biotechnology firm in China.

Founded in 2010, with its headquarters in Fuzhou in China, Yingke Capital is a principal investment firm specializing in pre-IPO investments. It seeks to invest in 5G IoT, biomedical, environmental and facilities services, new energy, consumer upgrade, smart manufacturing and materials sector.